April 21, 2010 – A stent that captures endothelial progenitor cells is now combined with thin cobalt chromium stent struts with a low profile for greater flexibility and deliverability. The Genous Bio-Engineered Cobalt Chromium Stent recently received CE mark approval for commercial release in Europe.
The L605 cobalt chromium bare metal stent uses a dual helix stent design for good radial strength utility in bifurcation stenting. The combination of the Genous technology with the new platform provides physicians with a stent designed to modulate restenosis and protect against thrombosis.
"The cobalt chromium Genous stent will allow us to use its superior mechanical properties to provide further treatment options in tortuous, complex or distal coronary disease, especially in those patients in whom prolonged dual anti-platelet therapy is undesirable," said Dr. Smith from Morriston Hospital, Swansea, Wales, United Kingdom.
Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology, which accelerates the natural healing process of the vessel wall after stent implantation. The technology consists of an antibody surface coating that captures EPCs circulating in the blood, which form a functional endothelial layer that provides protection against thrombosis and modulates restenosis.
OrbusNeich's Genous Bio-Engineered R stent has been commercially available in more than 60 countries since 2005. The Genous stent is offered as an alternative to drug-eluting stents.
For more information: www.OrbusNeich.com
April 17, 2024 
